Table 2.

Clinical baseline characteristics of patients with THSD7A-associated MN

Clinical CharacteristicsProspective Hamburg Cohort: 345 PatientsRetrospective Hamburg Cohort: 689 PatientsBoston Cohort: 242 PatientsCombined Patient Cohorts: 1276 Patients
No. of patients with THSD7A-associated MN (% of the respective cohort population)9 (2.6)20 (2.9)11 (4.5)40 (3.1)
Age, yr, median, IQR47, 39–6167, 55.25–7651, 33–6660.5, 46–73.25
Men (%)3 (33)11 (55)3 (27)17 (43)
Proteinuria, g/24 h, median, IQR5.4, 4.0–6.97.2, 4.3–9.9 (n=16)5.9, 3.0–7.7 (n=11)6.7, 3.7–8.6 (n=36)
Serum creatinine, mg/dl, median, IQR0.8, 0.6–0.91.3, 1.0–2.0 (n=16)0.8, 0.8–1.5 (n=9)1.0, 0.8–1.5 (n=34)
Time from renal biopsy to study inclusion, mo, median, IQR0.75, 0.5–0.81.0, 0.0–12.31.0, 0.3–25.51.0, 0.0–11.6
No. of patients with THSD7A-associated MN and malignancy (% of the respective THSD7A–associated MN population)3 (33.3)4 (20.0)1 (9.1)8 (20.0)
  • Data on proteinuria and serum creatinine were available for 36 and 34 patients, respectively. In 29 patients, the time between renal biopsy (and diagnosis of MN) and study inclusion (and serum collection for PLA2R1-Ab and THSD7A-Ab measurement) was <6 months. IQR, interquartile range.